How fibrosis influences imaging and surgical decisions in pancreatic cancer

Frontiers in Physiology

Volumn 3 OCT, Issue , 2012, Pages

  Erkan, Mert ^a   Hausmann, Simone ^a   Michalski, Christoph W ^a   Schlitter, Anna M ^b   Fingerle, Alexander A ^a   Dobritz, Martin ^a   Friess, Helmut ^a   Kleeff, Jörg ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angiogenesis; Cystic pancreatic tumors; Desmoplasia; Microenvironment; Molecular diagnostics; Periostin; Stellate cells

Indexed keywords

EID: 84870871667     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2012.00389     Document Type: Article

References (133)

1. Ahmed,N.,Pansino,F.,Clyde,R., Murthi,P.,Quinn,M.A.,Rice,G. E., et al. (2002). Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis 23, 237-244.
2. Allendorf, J. D., Lauerman, M., Bill, A., DiGiorgi, M., Goetz, N., Vakiani, E., et al. (2008). Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. J. Gastrointest. Surg. 12, 91-100.
3. Ansorge,C.,Strömmer,L.,AndrénSandberg, Å., Lundell, L., Herrington, M. K., and Segersvärd, R. (2012). Structured intraoperative assessment of pancreatic gland characteristics in predicting complications after pancreaticoduodenectomy. Br.J.Surg. 99, 1076-1082.
4. Apte, M. V., and Wilson, J. S. (2012). Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells. J. Gastroenterol. Hepatol. 27(Suppl. 2), 69-74.
5. Bachem, M. G., Schunemann, M., Ramadani, M., Siech, M., Beger, H., Buck, A., et al. (2005). Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128, 907-921.
6. Bandyopadhyay, A., and Raghavan, S. (2009). Defining the role of integrin alphavbeta6 in cancer. Curr. Drug Targets 10, 645-652.
7. Barcellos-Hoff, M. H., and Ravani, S. A. (2000). Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60, 1254-1260.
8. Bartoli, F. G., Arnone, G. B., Ravera, G., and Bachi, V. (1991). Pancreatic fistula and relative mortality in malignant disease after pancreaticoduodenectomy. Review and statistical meta-analysis regarding 15 years of literature. Anticancer Res. 11, 1831-1848.
9. Bassi, C., Dervenis, C., Butturini, G., Fingerhut, A., Yeo, C., Izbicki, J., et al. (2005a). Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138, 8-13.
10. Bassi, C., Falconi, M., Molinari, E., Salvia, R., Butturini, G., Sartori, N., et al. (2005b). Reconstruction by pancreaticojejunostomy versus pancreaticogastrostomy following pancreatectomy: results of a comparative study. Ann. Surg. 242, 767-771. discussion: 771-773.
11. Beane, J. D., Pitt, H. A., Nakeeb, A., Schmidt, C. M., House, M. G., Zyromski, N. J., et al. (2011). Splenic preserving distal pancreatectomy: does vessel preservation matter? J. Am. Coll. Surg. 212, 651-657. discussion: 657-658.
12. Buck, A. C., Schirrmeister, H. H., Guhlmann, C. A., Diederichs, C. G., Shen, C., Buchmann, I., et al. (2001). Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J. Nucl. Med. 42, 721-725.
13. Canto, M. I. (2007). Strategies for screening for pancreatic adenocarcinoma in high-risk patients. Semin. Oncol. 34, 295-302.
14. Canto, M. I., Hruban, R. H., Fishman, E.K.,Kamel,I.R.,Schulick,R., Zhang, Z., et al. (2012). Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142, 796-804.
15. Conroy, T., Gavoille, C., and Adenis, A. (2011). Metastatic pancreatic cancer: old drugs, new paradigms. Curr. Opin. Oncol. 23, 390-395.
16. Cruz-Monserrate, Z., Abd-Elgaliel, W.R.,Grote,T.,Deng,D.,Ji, B., Arumugam, T., et al. (2011). Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models. Gut 61, 1315-1322.
17. Di Carlo, V., Chiesa, R., Pontiroli, A. E., Carlucci, M., Staudacher, C., Zerbi, A., et al. (1989). Pancreatoduodenectomy with occlusion of the residual stump by Neoprene injection. World J. Surg. 13, 105-110. discussion: 110-111.
18. Diener, M. K., Seiler, C. M., Rossion, I., Kleeff, J., Glanemann, M., Butturini, G., et al. (2011). Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet 377, 1514-1522.
19. Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., and Jain, R. K. (2011). Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. U.S.A. 108, 2909-2914.
20. Duffas,J.P.,Suc,B.,Msika,S., Fourtanier, G., Muscari, F., Hay, J. M., et al. (2005). A controlled randomized multicenter trial of pancreatogastrostomy or pancreatojejunostomy after pancreatoduodenectomy. Am. J. Surg. 189, 720-729.
21. Erkan,M.,Adler,G.,Apte,M.V., Bachem, M. G., Buchholz, M., Detlefsen, S., et al. (2012a). StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut 61, 172-178.
22. Erkan, M., Hausmann, S., Michalski, C. W., Fingerle, A. A., Dobritz, M., Kleeff, J., et al. (2012b). The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat. Rev. Gastroenterol. Hepatol.9, 454-467.
23. Erkan, M., Reiser-Erkan, C., Michalski, C. W., Kong, B., Esposito, I., Friess, H., et al. (2012c). The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. Curr. Mol. Med. 12, 288-303.
24. Erkan, M., Kleeff, J., Esposito, I., Giese, T., Ketterer, K., Buchler, M. W., et al. (2005). Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance andworsenedprognosis.Oncogene 24, 4421-4432.
25. Erkan, M., Kleeff, J., Gorbachevski, A.,Reiser,C.,Mitkus,T.,Esposito, I., et al. (2007a). Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 132, 1447-1464.
26. Erkan, M., Kleeff, J., Reiser, C., Hinz, U., Esposito, I., Friess, H., et al. (2007b). Preoperative acute pancreatitis in periampullary tumors: implications for surgical management. Digestion 75, 165-171.
27. Erkan, M., Michalski, C. W., Rieder, S., Reiser-Erkan, C., Abiatari, I., Kolb, A., et al. (2008). The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 6, 1155-1161.
28. Erkan, M., Reiser-Erkan, C., Michalski, C. W., Deucker, S., Sauliunaite, D., Streit, S., et al. (2009). Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 11, 497-508.
29. Erkan, M., Reiser-Erkan, C., Michalski, C. W., and Kleeff, J. (2010). Tumor microenvironment and progression of pancreatic cancer. Exp. Oncol. 32, 128-131.
30. Werder,A.,Seidler,B.,Bajbouj, M., et al. (2011). In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging. Proc. Natl. Acad. Sci. U.S.A. 108, 9945-9950.
31. Farace, P., Merigo, F., Fiorini, S., Nicolato, E., Tambalo, S., Daducci, A., et al. (2011). DCE-MRI using small-molecular and albuminbinding contrast agents in experimental carcinomas with different stromal content. Eur. J. Radiol. 78, 52-59.
32. Fearon, E. R., and Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
33. Fernandez-Cruz, L., Cosa, R., Blanco, L., Lopez-Boado, M. A., and Astudillo, E. (2008). Pancreatogastrostomy with gastric partition after pyloruspreserving pancreatoduodenectomy versus conventional pancreatojejunostomy: a prospective randomized study. Ann. Surg. 248, 930-938.
34. Fern and ez-del Castillo, C., and Warshaw, A. L. (2001). Cystic neoplasms of the pancreas. Pancreatology 1, 641-647.
35. Ferrone, C. R., Konstantinidis, I. T., Sahani, D. V., Wargo, J. A., Fern and ez-del Castillo, C., and Warshaw, A. L. (2011). Twenty-three years of the Warshaw operation for distal pancreatectomy with preservation of the spleen. Ann. Surg. 253, 1136-1139.
36. Filippou, D. K., Kolimpiris, C., Anemodouras, N., and Rizos, S. (2004). Modified capitonage in partial cystectomy performed for liver hydatid disease: report of 2 cases. BMC Surg. 4, 8.
37. Frozanpor, F., Lundell, L., Segersvard, R., and Arnelo, U. (2012). The effect of prophylactic transpapillary pancreatic stent insertion on clinically significant leak rate following distal pancreatectomy: results of a prospective controlled clinical trial. Ann. Surg. 255, 1032-1036.
38. Furukawa, T., Hatori, T., Fujita, I., Yamamoto, M., Kobayashi, M., Ohike, N., et al. (2011). Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut 60, 509-516.
39. Gans, S. L., van Westreenen, H. L., Kiewiet, J. J., Rauws, E. A., Gouma, D. J., and Boermeester, M. A. (2012). Systematic review and metaanalysis of somatostatin analogues for the treatment of pancreatic fistula. Br.J.Surg.99, 754-760.
40. Gatenby, R. A., and Gillies, R. J. (2008). A microenvironmental model of carcinogenesis. Nat. Rev. Cancer 8, 56-61.
41. Gaujoux, S., Cortes, A., Couvelard, A., Noullet, S., Clavel, L., Rebours, V., et al. (2010). Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy. Surgery 148, 15-23.
42. Goldsmith, H. S., Ghosh, B. C., and Huvos, A. G. (1971). Ligation versus implantation of the pancreatic duct after pancreaticoduodenectomy. Surg. Gynecol. Obstet. 132, 87-92.
43. Guerra, C., Schuhmacher, A. J., Canamero,M.,Grippo,P.J., Verdaguer, L., Perez-Gallego, L., et al. (2007). Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer cell 11, 291-302.
44. Guturu, P., Shah, V., and Urrutia, R. (2009). Interplay of tumor microenvironment cell types with parenchymal cells in pancreatic cancer development and therapeutic implications. J. Gastrointest. Cancer 40, 1-9.
45. Hamilton,N.A.,Porembka,M.R., Johnston, F. M., Gao, F., Strasberg, S. M., Linehan, D. C., et al. (2012). Mesh reinforcement of pancreatic transection decreases incidence of pancreatic occlusion failure for left pancreatectomy: a single-blinded, randomized controlled trial. Ann. Surg. 255, 1037-1042.
46. Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70.
47. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
48. Herrmann,K.,Erkan,M.,Dobritz,M., Schuster, T., Siveke, J. T., Beer, A. J., et al. (2012). Comparison of 3' deoxy 3'-[(18)F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Eur. J. Nucl. Med. Mol. Imaging 39, 846-851.
49. Holzapfel, K., Reiser-Erkan, C., Fingerle,A.A.,Erkan,M.,Eiber, M. J., Rummeny, E. J., et al. (2011). Comparison of diffusion-weighted MR imaging and multidetectorrow CT in the detection of liver metastases in patients operated for pancreatic cancer. Abdom. Imaging 36, 179-184.
50. Hwang, R. F., Moore, T., Arumugam, T., Ramachandran, V., Amos, K. D., Rivera, A., et al. (2008). Cancerassociated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68, 918-926.
51. Ishikawa,O.,Ohigashi,H.,Imaoka,S., Teshima, T., Inoue, T., Sasaki, Y., et al. (1991). Concomitant benefit of preoperative irradiation in preventing pancreas fistula formation after pancreatoduodenectomy. Arch. Surg. 126,885-889.
52. Jacobetz,M.A.,Chan,D.S.,Neesse,A., Bapiro,T.E.,Cook,N.,Frese,K.K., et al. (2012). Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. doi: 10.1136/gutjnl-2012302529 [Epub ahead of print].
53. Jaeschke, A., Dennis, P. B., and Thomas, G. (2004). mTOR: a mediator of intracellular homeostasis. Curr. Top. Microbiol. Immunol. 279, 283-298.
54. Jemal,A.,Bray,F.,Center,M.M., Ferlay,J.,Ward,E.,andForman,D. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69-90.
55. Juweid, M. E., and Cheson, B. D. (2006). Positron-emission tomography and assessment of cancer therapy. N. Engl. J. Med. 354, 496-507.
56. Kato, T., Lobritto, S. J., Tzakis, A., Raveh, Y., Sandoval, P. R., Martinez, M., et al. (2012). Multivisceral ex vivo surgery for tumors involving celiac and superior mesenteric arteries. Am. J. Transplant. 12, 1323-1328.
57. Kelloff, G. J., Hoffman, J. M., Johnson, B.,Scher,H.I.,Siegel,B.A.,Cheng, E. Y., et al. (2005). Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin. Cancer Res. 11, 2785-2808.
58. Kelly, K. A., Bardeesy, N., Anbazhagan, R., Gurumurthy, S., Berger, J., Alencar, H., et al. (2008). Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med. 5:e85. doi: 10.1371/journal.pmed.0050085
59. Kessenbrock, K., Plaks, V., and Werb, Z. (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67.
60. Kim, Y. H., Sung, H. J., Kim, S., Kim, E. O., Lee, J. W., Moon, J. Y., et al. (2011). An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. Cancer Lett. 313, 76-83.
61. Kimura, R. H., Teed, R., Hackel, B. J.,Pysz,M.A.,Chuang,C.Z., Sathirachinda, A., et al. (2012). Pharmacokinetically stabilized cystine knot peptides that bind alphav-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin. Cancer Res. 18, 839-849.
62. Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., et al. (2010). Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group, B (CALGB 80303). J. Clin. Oncol. 28, 3617-3622.
63. Kinzler, K. W., and Vogelstein, B. (1996). Lessons from hereditary colorectal cancer. Cell 87, 159-170.
64. Kleeff, J., Diener, M. K., Z'Graggen, K., Hinz, U., Wagner, M., Bachmann, J., et al. (2007). Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann. Surg. 245, 573-582.
65. Kloppel, G., Detlefsen, S., and Feyerabend, B. (2004). Fibrosis of the pancreas: the initial tissue damage and the resulting pattern. Virchows Arch. 445, 1-8.
66. Knaebel, H. P., Diener, M. K., Wente, M. N., Buchler, M. W., and Seiler, C. M. (2005). Systematic review and meta-analysis of technique for closure of the pancreatic remnant after distal pancreatectomy. Br. J. Surg. 92, 539-546.
67. Koong,A.C.,Denko,N.C.,Hudson,K. M.,Schindler,C.,Swiersz,L.,Koch, C., et al. (2000a). Candidate genes for the hypoxic tumor phenotype. Cancer Res. 60, 883-887.
68. Koong,A.C.,Mehta,V.K.,Le,Q.T., Fisher, G. A., Terris, D. J., Brown, J. M., et al. (2000b). Pancreatic tumors show high levels of hypoxia. Int. J. Rad. Oncol. Biol. Phys. 48, 919-922.
69. Kosmahl, M., Wagner, J., Peters, K., Sipos, B., and Kloppel, G. (2004). Serous cystic neoplasms of the pancreas: an immunohistochemical analysis revealing alpha-inhibin, neuron-specific enolase, and MUC6 as new markers. Am. J. Surg. Pathol. 28, 339-346.
70. Kurohi, T., Tajima, Y., Tsuneoka, N.,Adachi,T.,andKanematsu, T. (2010). Dynamic contrastenhanced magnetic resonance imaging to predict pancreatic fistula after distal pancreatectomy. Hepatogastroenterology 57, 1539-1542.
71. Laffan, T. A., Horton, K. M., Klein, A. P., Berlanstein, B., Siegelman, S. S., Kawamoto, S., et al. (2008). Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am. J. Roentgenol. 191, 802-807.
72. Lassalle, H. P., Marchal, S., Guillemin, F., Reinhard, A., and Bezdetnaya, L. (2012). Aptamers as remarkable diagnostic and therapeutic agents in cancer treatment. Curr. Drug Metab. PMID: 22380008. [Epub ahead of print].
73. Lee, S. E., Jang, J. Y., Lim, C. S., Kang, M.J.,Kim,S.H.,Kim,M.A., et al. (2010). Measurement of pancreatic fat by magnetic resonance imaging: predicting the occurrence of pancreatic fistula after pancreatoduodenectomy. Ann. Surg. 251, 932-936.
74. Lillemoe, K. D., Kaushal, S., Cameron, J.L.,Sohn,T.A.,Pitt,H.A.,andYeo, C. J. (1999). Distal pancreatectomy: indications and outcomes in 235 patients. Ann. Surg. 229, 693-698. discussion: 698-700.
75. Lowenfels, A. B., Maisonneuve, P., Cavallini, G., Ammann, R. W., Lankisch,P.G.,Andersen,J.R.,etal. (1993). Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N. Engl. J. Med. 328, 1433-1437.
76. Lunevicius, R., Nakanishi, H., Ito, S., Kozaki, K., Kato, T., Tatematsu, M., et al. (2001). Clinicopathological significance of fibrotic capsule formation around liver metastasis from colorectal cancer. J. Cancer Res. Clin. Oncol. 127, 193-199.
77. Mahmood, U., and Weissleder, R. (2002). Some tools for molecular imaging. Acad. Radiol. 9, 629-631.
78. Maire,F.,Hammel,P.,Terris,B., Paye,F.,Scoazec,J.Y.,Cellier,C., et al. (2002). Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut 51, 717-722.
79. Masamune, A., Kikuta, K., Watanabe, T., Satoh, K., Hirota, M., Hamada, S., et al. (2009). Fibrinogen induces cytokine and collagen production in pancreatic stellate cells. Gut 58, 550-559.
80. Matsumoto, T., Hirano, S., Yada, K., Shibata, K., Sasaki, A., Kamimura, T., et al. (2005). Malignant serous cystic neoplasm of the pancreas: report of a case and review of the literature. J. Clin. Gastroenterol. 39, 253-256.
81. Matthaei, H., Schulick, R. D., Hruban, R. H., and Maitra, A. (2011). Cystic precursors to invasive pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 8, 141-150.
82. Michalski, C. W., Erkan, M., Huser, N., Muller, M. W., Hartel, M., Friess, H., et al. (2008a). Resection of primary pancreatic cancer and liver metastasis: a systematic review. Dig. Surg. 25, 473-480.
83. Michalski, C. W., Kleeff, J., Bachmann, J., Alkhatib, J., Erkan, M., Esposito, I., et al. (2008b). Second-look operation for unresectable pancreatic ductal adenocarcinoma at a highvolume center. Ann. Surg. Oncol. 15, 186-192.
84. Okabayashi, T., Kobayashi, M., Nishimori, I., Sugimoto, T., Onishi, S., and Hanazaki, K. (2007). Risk factors, predictors and prevention of pancreatic fistula formation after pancreatoduodenectomy. J. Hepatobiliary Pancreat. Surg. 14, 557-563.
85. Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., et al. (2009). Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461.
86. Pandol, S., Edderkaoui, M., Gukovsky, I.,Lugea,A.,andGukovskaya, A. (2009). Desmoplasia of pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 7(Suppl. 11), S44-S47.
87. Panozzo, M. P., Basso, D., Plebani, M.,Valente,M.L.,Rasia,E.,and Balint, L. (1995). Effects of pancreaticobiliary duct obstruction on the exocrine and endocrine rat pancreas. Pancreas 11, 408-414.
88. Perez-Mancera, P. A., Guerra, C., Barbacid, M., and Tuveson, D. A. (2012). What we have learned about pancreatic cancer from mouse models. Gastroenterology 142, 1079-1092.
89. Pessaux, P., Sauvanet, A., Mariette, C., Paye,F.,Muscari,F.,Cunha,A. S., et al. (2011). External pancreatic duct stent decreases pancreatic fistula rate after pancreaticoduodenectomy: prospective multicenter randomized trial. Ann. Surg. 253, 879-885.
90. Phillips,P.A.,Yang,L.,Shulkes, A.,Vonlaufen,A.,Poljak,A., Bustamante, S., et al. (2010). Pancreatic stellate cells produce acetylcholine and may play a role in pancreatic exocrine secretion. Proc. Natl. Acad. Sci. U.S.A. 107, 17397-17402.
91. Picard, F. J., and Bergeron, M. G. (2002). Rapid molecular theranostics in infectious diseases. Drug Discov. Today 7, 1092-1101.
92. Poon, R. T., and Fan, S. T. (2008). Decreasing the pancreatic leak rate after pancreaticoduodenectomy. Adv. Surg. 42, 33-48.
93. Poon,R.T.,Fan,S.T.,Lo,C.M., Ng,K.K.,Yuen,W.K.,Yeung, C., et al. (2007). External drainage of pancreatic duct with a stent to reduce leakage rate of pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial. Ann. Surg. 246, 425-433. discussion: 433-435.
94. Provenzano, P. P., Eliceiri, K. W., Campbell,J.M.,Inman,D.R., White, J. G., and Keely, P. J. (2006). Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med. 4, 38.
95. Radisky,D.C.,andPrzybylo,J.A. (2008). Matrix metalloproteinaseinduced fibrosis and malignancy in breast and lung. Proc. Am. Thorac. Soc. 5, 316-322.
96. Radisky, E. S., and Radisky, D. C. (2010). Matrix metalloproteinaseinduced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland Biol. Neoplasia 15, 201-212.
97. Reddy,R.P.,Smyrk,T.C.,Zapiach, M., Levy, M. J., Pearson, R. K., Clain, J. E., et al. (2004). Pancreatic mucinous cystic neoplasm defined by ovarian stroma: demographics, clinical features, and prevalence of cancer. Clin. Gastroenterol. Hepatol. 2, 1026-1031.
98. Roder,J.D.,Stein,H.J.,Bottcher,K. A.,Busch,R.,Heidecke,C.D.,and Siewert, J. R. (1999). Stented versus nonstented pancreaticojejunostomy after pancreatoduodenectomy: a prospective study. Ann. Surg. 229, 41-48.
99. Rozen, P., Liphshitz, I., Rosner, G., Barchana,M.,Lachter,J.,Pel,S., et al. (2009). Pancreatic cancer in Israel: the epidemiology, possibilities of prevention, early detection and screening. Isr. Med. Assoc. J. 11, 710-713.
100. Salvia, R., Fern and ez-del Castillo, C., Bassi,C.,Thayer,S.P.,Falconi,M., Mantovani, W., et al. (2004). Mainduct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and longterm survival following resection. Ann. Surg. 239, 678-685. discussion: 685-687.
101. Samkharadze, T., Erkan, M., Reiser-Erkan, C., Demir, I. E., Kong, B., Ceyhan, G. O., et al. (2011). Pigment epithelium-derived factor associates with neuropathy and fibrosis in pancreatic cancer. Am. J. Gastroenterol. 106, 968-980.
102. Sato, N., Yamaguchi, K., Chijiiwa, K., and Tanaka, M. (1998). Risk analysis of pancreatic fistula after pancreatic head resection. Arch. Surg. 133, 1094-1098.
103. Schneider, G., Siveke, J. T., Eckel, F., and Schmid, R. M. (2005). Pancreatic cancer: basic and clinical aspects. Gastroenterology 128, 1606-1625.
104. Shankar, A., and Russell, R. C. (2001). Recent advances in the surgical treatment of pancreatic cancer. World J. Gastroenterol. 7, 622-626.
105. Shields, A. F., Grierson, J. R., Dohmen, B. M., Machulla, H. J., Stayanoff, J. C., Lawhorn-Crews, J. M., et al. (1998). Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 4, 1334-1336.
106. Shrikhande, S. V., Qureshi, S. S., Rajneesh,N.,andShukla,P.J. (2005). Pancreatic anastomoses after pancreaticoduodenectomy: do we need further studies? World J. Surg. 29, 1642-1649.
107. Sohn, T. A., Yeo, C. J., Cameron, J. L., Hruban, R. H., Fukushima, N., Campbell, K. A., et al. (2004). Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann. Surg. 239, 788-797. discussion: 797-799.
108. Sternlicht,M.D.,Lochter,A.,Sympson, C.J.,Huey,B.,Rougier,J.P.,Gray, J. W., et al. (1999). The stromal proteinase MMP3/stromelysin1 promotes mammary carcinogenesis. Cell 98, 137-146.
109. Strobel, O., Berens, V., Hinz, U., Hartwig, W., Hackert, T., Bergmann, F., et al. (2012). Resection after neoadjuvant therapy for locally advanced, unresectable pancreatic cancer. Surgery 152(3 SUPPL. 1), S33-S42.
110. Stumpf, M., Junge, K., Wendlandt, M.,Krones,C.,Ulmer,F.,Klinge, U., et al. (2009). [Risk factors for anastomotic leakage after colorectal surgery]. Zentralblatt fur Chirurgie 134, 242-248.
111. Suc,B.,Msika,S.,Fingerhut,A., Fourtanier, G., Hay, J. M., Holmieres, F., et al. (2003). Temporary fibrin glue occlusion of the main pancreatic duct in the prevention of intra-abdominal complications after pancreatic resection: prospective randomized trial. Ann. Surg. 237, 57-65.
112. Suzuki, Y., Kuroda, Y., Morita, A., Fujino, Y., Tanioka, Y., Kawamura, T., et al. (1995). Fibrin glue sealing for the prevention of pancreatic fistulas following distal pancreatectomy. Arch. Surg. 130, 952-955.
113. Tanaka,M.,Chari,S.,Adsay,V., Fern and ez-del Castillo, C., Falconi, M., Shimizu, M., et al. (2006). International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6, 17-32.
114. Tanaka, M., Fern and ez-Del Castillo, C.,Adsay,V.,Chari,S.,Falconi, M., Jang, J. Y., et al. (2012). International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12, 183-197.
115. Tanaka, T., Ichiba, Y., Fujii, Y., Itoh, H., Kodama, O., and Dohi, K. (1988). New canine model of chronic pancreatitis due to chronic ischemia with incomplete pancreatic duct obstruction. Digestion 41, 149-155.
116. Tang, L. H., Aydin, H., Brennan, M. F., and Klimstra, D. S. (2005). Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. Am.J.Surg.Pathol.29, 512-519.
117. Tran, K., Van Eijck, C., Di Carlo, V., Hop, W. C., Zerbi, A., Balzano, G., et al. (2002). Occlusion of the pancreatic duct versus pancreaticoje-junostomy: a prospective randomized trial. Ann. Surg. 236, 422-428. discussion: 428.
118. Vande Walle, C., Ceelen, W. P., Boterberg, T., Vande Putte, D., Van Nieuwenhove, Y., Varin, O., et al. (2012). Anastomotic complications after Ivor Lewis esophagectomy in patients treated with neoadjuvant chemoradiation are related to radiation dose to the gastric fundus. Int. J. Rad. Oncol. Biol. Phys. 82, e513-e519.
119. Venkatasubramanian, P. N. (2012). "Imaging the pancreatic ECM," in Pancreatic Cancer and Tumor Microenvironment, eds P. J. Grippo and H. G. Munshi (Trivandrum, India: Transworld Research Network). ISBN-13: 978-81-7895-548-3
120. Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., et al. (2011). Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Cin. Oncol. 29, 4548-4554.
121. Vonlaufen, A., Joshi, S., Qu, C., Phillips, P. A., Xu, Z., Parker, N. R., et al. (2008a). Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 68, 2085-2093.
122. Vonlaufen, A., Phillips, P. A., Xu, Z., Goldstein, D., Pirola, R. C., Wilson, J. S., et al. (2008b). Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. Cancer Res. 68, 7707-7710.
123. Wada, K., Kozarek, R. A., and Traverso, L. W. (2005). Outcomes following resection of invasive and noninva-sive intraductal papillary mucinous neoplasms of the pancreas. Am. J. Surg. 189, 632-636. discussion: 637.
124. Wente, M. N., Shrikhande, S. V., Muller, M. W., Diener, M. K., Seiler, C. M., Friess, H., et al. (2007). Pancreaticojejunostomy versus pancreaticogastrostomy: systematic review and meta-analysis. Am. J. Surg. 193, 171-183.
125. Winter, J. M., Brennan, M. F., Tang, L. H., D'Angelica, M. I., Dematteo, R. P., Fong, Y., et al. (2012). Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann. Surg. Oncol. 19, 169-175.
126. Winter, J. M., Cameron, J. L., Campbell, K. A., Chang, D. C., Riall, T. S., Schulick, R. D., et al. (2006). Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial. J. Gastrointest. Surg. 10, 1280-1290. discussion: 1290.
127. Xu, Z., Vonlaufen, A., Phillips, P. A., Fiala-Beer, E., Zhang, X., Yang, L., et al. (2010). Role of pancreatic stellate cells in pancreatic cancer metastasis. Am. J. Pathol. 177, 2585-2596.
128. Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., et al. (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117.
129. Yamao, K., Ohashi, K., Nakamura, T., Suzuki, T., Shimizu, Y., Nakamura, Y., et al. (2000). The prognosis of intraductal papillary mucinous tumors of the pancreas. Hepatogastroenterology 47, 1129-1134.
130. Yeo, C. J., Cameron, J. L., Lillemoe, K. D., Sitzmann, J. V., Hruban, R. H., Goodman, S. N., et al. (1995a). Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann. Surg. 221, 721-731. discussion: 731-733.
131. Yeo, C. J., Cameron, J. L., Maher, M. M., Sauter, P. K., Zahurak, M. L., Talamini, M. A., et al. (1995b). A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann. Surg. 222, 580-588. discussion: 588-592.
132. Zaman, M. B., Baral, T. N., Jakubek, Z. J., Zhang, J., Wu, X., Lai, E., et al. (2011). Single-domain antibody bioconjugated near-IR quantum dots for targeted cellular imaging of pancreatic cancer. J. Nanosci. Nanotechnol. 11, 3757-3763.
133. Zhuo, S., Chen, J., Xie, S., Hong, Z., and Jiang, X. (2009). Extracting diagnostic stromal organization features based on intrinsic two-photon excited fluorescence and second-harmonic generation signals. J. Biomed. Optics 14, 020503.